NCT06092333View on ClinicalTrials.gov

VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

February 29, 2028

Study Completion Date

August 31, 2028

Conditions
Chronic Hepatitis B
Interventions
DRUG

VIR-2218 and peginterferon alfa-2a

(VIR-2218) administered as a lead-in followed by combination with peginterferon alfa-2a

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH